Loading
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (1 ops.)
Latest filing published 23 Feb 2026 for Cullinan Therapeutics, Inc., €51k. Read the official filing
Filing timeline
BuySaleMary Kay Fenton
Insider track record
Disclosed buys
0
Disclosed sells
1
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Mary Kay Fenton: trading record in brief
This profile gathers the share dealings of Mary Kay Fenton across 2 companies, led by Cullinan Therapeutics, Inc. and Talaris Therapeutics, Inc. The record holds 7 filings, for trades running from 31 December 2021 to 20 February 2026.
Sales make up the whole of the open-market record (1 sale, €51k). The rest of the record consists of 6 share grants. In 2026 alone, the filings show no purchases and 1 sale.
On 23 February 2026 came the latest disclosure, an open-market sale for €51k in Cullinan Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 3 days. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Mary Kay Fenton
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations7 total
4,398 shares@ US$13.6299.7% of flowCommon StockSEC:0001193125-26-064261:0
68,750 shares0Common StockSEC:0001193125-26-059637:0
27 shares@ US$6.490.3% of flowCommon StockSEC:0001193125-26-002687:0
60,000 shares0Common StockSEC:0000950170-25-025027:0
12,946 shares@ US$3.0861.4% of flowCommon StockSEC:0001209191-23-041617:0
80,000 shares0Common StockSEC:0000899243-22-030928:0
1,000 shares@ US$13.0023.9% of flowCommon StockSEC:0000899243-22-004201:0
7 of 7 declarations
